Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Revagenix Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, which means the company's current pending matters are under the review of this individual. The data shows 1 distinct art unit is involved in the prosecution of this portfolio. This count of 1 distinct art unit indicates that the technical scope of the pending work is handled by an administrative group within the patent office.
The busiest examiner identified is KRISHNAN, GANAPATHY, who is responsible for 1 busiest examiner pending office action. Because this examiner holds the 1 busiest examiner pending office action, their examination history is a factor in the portfolio's progress. The presence of 1 distinct examiner and the 1 pending office action indicates that there is no distribution of work across multiple office sections at this time. Practitioners should monitor the prosecution for Revagenix Inc. in this Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18821366 | BROAD SPECTRUM AMINOGLYCOSIDES AND USES THEREOF | KRISHNAN, GANAPATHY | 1693 | §103§112DP | Non-Final OA | — | Pending | Aug 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRevagenix Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ganapathy Krishnan has the most, with 1 of Revagenix Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.